Cy­ti­va's lat­est project to open in Switzer­land at the end of the month

Glob­al life sci­ences com­pa­ny Cy­ti­va hasn’t been shy about its plans to pump mon­ey in­to ex­pand­ing glob­al op­er­a­tions. Tues­day, it an­nounced that it would open the doors at its lat­est big man­u­fac­tur­ing site in Eu­rope in a move that will quadru­ple its man­u­fac­tur­ing ca­pac­i­ty.

Cy­ti­va’s new site in Grens, Switzer­land will house its Cen­ter of Ex­cel­lence for cell and gene ther­a­pies and will be used in reg­u­la­to­ry-ap­proved ther­a­pies and clin­i­cal tri­als.

The near­ly 80,000 square-feet site will be open for busi­ness on May 31. The site will man­u­fac­ture sin­gle-use kits for Sep­ax and Se­fia cell pro­cess­ing sys­tems, and con­sum­ables for Xuri cell ex­pan­sion sys­tems. It will al­so serve as a home base for Eu­ro­pean cus­tomers and their train­ing pro­grams. 250 em­ploy­ees are set to work here at the start. A ground­break­ing cer­e­mo­ny will be held on May 31 to mark the event.

Cata­ri­na Fly­borg

“Cell and gene ther­a­pies have the po­ten­tial to change the glob­al health­care land­scape,” said Cata­ri­na Fly­borg VP of C&G Ther­a­py at Cy­ti­va. “Our new fa­cil­i­ty in Grens will en­able us to meet glob­al de­mand for our prod­ucts, while work­ing with our cus­tomers to meet their im­me­di­ate train­ing and de­vel­op­ment needs. This fa­cil­i­ty brings us an­oth­er step clos­er to our vi­sion where ac­cess to life-chang­ing ther­a­pies trans­forms hu­man health.”

The al­ready-ex­ist­ing site in Eysins will keep op­er­at­ing through the end of next year, while full pro­duc­tion is trans­ferred to the newest site in Grens. The new site has been built to Swiss Min­ergie stan­dards, and is pow­ered by 100% re­new­able elec­tric­i­ty and has mount­ed so­lar pan­els on the roof. The com­pa­ny said that the dy­nam­ic clean­room con­trols could re­duce the amount of en­er­gy it us­es by 60%.

Philippe Leu­ba

“Cy­ti­va is one of the world’s lead­ing life sci­ences com­pa­nies,” said Philippe Leu­ba, Switzer­land’s Min­is­ter of Eco­nom­ic Af­fairs, in a state­ment. “Its de­ci­sion to ex­pand op­er­a­tions in Switzer­land is a tes­ta­ment to our in­no­va­tion ecosys­tem that has played a sig­nif­i­cant role in de­vel­op­ing some of the most ad­vanced ther­a­peu­tics.”

Cy­ti­va has pledged $1.5 bil­lion to ex­pand its man­u­fac­tur­ing op­er­a­tions around the world, as it looks to shift the fo­cus to in-re­gion, for-re­gion man­u­fac­tur­ing. In March, it opened a new 118,400 square-foot site in Cardiff, Wales that’s fo­cused on man­u­fac­tur­ing sin­gle-use bio­pro­cess­ing tech. That site will serve cus­tomers around the world, but pro­vide cus­tomers in the UK and Eu­rope with a clos­er op­er­a­tion to work with. That site will fo­cus on Cy­ti­va’s can­cer, au­toim­mune and rare dis­ease drug clients, as well as Covid-19 vac­cines.

It al­so has pledged $52.5 mil­lion in South Ko­rea for the man­u­fac­tur­ing of cell cul­ture flu­id, which at the time, was in very short sup­ply. It ex­pand­ed two lo­ca­tions in cen­tral Mass­a­chu­setts in 2020 with the ad­di­tion of 130 new jobs in West­bor­ough and an up­grade at its Shrews­bury site too.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Fireside chat between Hal Barron and John Carroll, UKBIO19

It’s time we talked about bio­phar­ma — live in Lon­don next week

Zoom can only go so far. And I think at this stage, we’ve all tested the limits of staying in touch — virtually. So I’m particularly happy now that we’ve revved up the travel machine to point myself to London for the first time in several years.

Whatever events we have lined up, we’ve always built in plenty of opportunities for all of us to get together and talk. For London, live, I plan to be right out front, meeting with and chatting with the small crowd of biopharma people we are hosting on October 12 at Silicon Valley Bank’s London headquarters. And there’s a lengthy mixer at the end I’m most looking forward to, with several networking openings between sessions.

Pfizer and BioNTech's original Marvel comic book links evolving Covid vaccine science to Avengers' evolving villain-fighting tools.(Source: Pfizer LinkedIn post)

Pfiz­er, BioN­Tech part­ner with Mar­vel for Avengers and Covid-fight­ing com­ic book

Pfizer and BioNTech are collaborating with Marvel to celebrate “everyday” people getting Covid-19 vaccines in a custom comic book.

In the “Everyday Heroes” digital comic book, an evolving Ultron, one of the Avengers’ leading villains, is defeated by Captain America, Ironman and others. The plotline and history of Ultron is explained by a grandfather who is waiting with his family at a clinic for Covid-19 vaccinations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Takeda on Tuesday morning made an announcement that almost 3,000 people with the rare disease known as hypoparathyroidism were fearing.

Due to unresolved supply issues and manufacturing woes, Takeda said it will cut its losses and discontinue its hypoparathyroidism drug, known as Natpara (parathyroid hormone), halting all manufacturing of the drug by the end of 2024, but the entire inventory will be available until depleted or expired, a company spokesperson said via email.

Eli Lil­ly and Te­va pre­pare for court bat­tle over mi­graine med ri­val­ry

It looks like Eli Lilly and Teva Pharmaceuticals are going to trial.

A federal appeals court on Monday refused to invalidate three of Teva’s patents for its migraine treatment Ajovy, while also declining to issue a summary judgment in favor of either company, which would effectively end the case without a full trial.

Teva filed suit against Lilly back in 2018, alleging that the company infringed upon nine patents with its rival migraine drug Emgality. The rival drugs were both approved in September 2018 for the preventative treatment of migraine, and are designed to block calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Tim Miller, Forge Biologics CEO

CNS-fo­cused gene ther­a­py biotech forges man­u­fac­tur­ing deal for hear­ing loss drug

A growing gene therapy company is teaming up with one of the largest gene therapy manufacturers to get its drug into patients in clinical trials.

Myrtelle announced on Monday that it inked a deal with Forge Biologics to make Myr-201, a gene therapy indicated for monogenic hearing loss. The target patient population, Myrtelle said, is people with a type of hearing loss called DFNB8, or autosomal recessive deafness 8.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Two CRLs lat­er, Illi­nois-based CD­MO hit with FDA warn­ing let­ter over 's­pore-form­ing' bac­te­ria and fun­gi

Dupo, IL-based contract manufacturer Sterling Pharmaceuticals has had a long, tough year.

Last September, partner Verrica Pharmaceuticals’ NDA for a potential skin disease treatment was hit with a second CRL, with the company pinning the problems on Sterling. Eight months later, Verrica was hit with a third CRL due to further issues at Sterling, following a February reinspection by FDA of the Sterling site.

Rep. Vern Buchanan (R-FL) (Bill Clark/CQ Roll Call via AP Images)

Af­ter cov­er­age re­stric­tions for Alzheimer's drugs, bi­par­ti­san House bill would force CMS to re­view drugs in­di­vid­u­al­ly

When Biogen’s controversial Alzheimer’s drug Aduhelm was hit with a national decision from CMS that restricted coverage to only randomized trials, practically guaranteeing a commercial flop in the near term, questions surfaced over why CMS also included all amyloid-targeted monoclonal antibodies for Alzheimer’s disease.

With Eisai and Biogen’s second Alzheimer’s drug, lecanemab, now showing it can slow the rate of cognitive decline versus placebo, lining up for a likely full approval next spring, the question now turns to whether that data, which is being presented at the Clinical Trials on Alzheimer’s Congress in San Francisco in late November, will be enough for CMS when it asks, “Does the anti-amyloid mAb meaningfully improve health outcomes (i.e., slow the decline of cognition and function) for patients in broad community practice?”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.